Telomir Pharmaceuticals (NASDAQ:TELO) Now Covered by Analysts at Rodman & Renshaw

Rodman & Renshaw began coverage on shares of Telomir Pharmaceuticals (NASDAQ:TELO) in a research note issued to investors on Friday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $15.00 price target on the stock.

Telomir Pharmaceuticals Stock Down 6.5 %

TELO opened at $3.91 on Friday. Telomir Pharmaceuticals has a 12-month low of $3.11 and a 12-month high of $9.54. The firm’s fifty day moving average price is $4.56 and its 200 day moving average price is $4.85.

Telomir Pharmaceuticals (NASDAQ:TELO) last issued its earnings results on Tuesday, February 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.05). As a group, research analysts predict that Telomir Pharmaceuticals will post -0.4 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC lifted its stake in Telomir Pharmaceuticals by 73.3% during the fourth quarter. Geode Capital Management LLC now owns 413,677 shares of the company’s stock worth $1,705,000 after purchasing an additional 174,940 shares during the last quarter. Northern Trust Corp lifted its position in shares of Telomir Pharmaceuticals by 211.5% in the 4th quarter. Northern Trust Corp now owns 151,628 shares of the company’s stock worth $625,000 after buying an additional 102,948 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Telomir Pharmaceuticals by 40.8% in the 4th quarter. Bank of New York Mellon Corp now owns 72,295 shares of the company’s stock valued at $298,000 after buying an additional 20,931 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Telomir Pharmaceuticals by 327.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 46,406 shares of the company’s stock valued at $191,000 after buying an additional 35,556 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of Telomir Pharmaceuticals by 1,096.4% during the 4th quarter. JPMorgan Chase & Co. now owns 41,444 shares of the company’s stock valued at $171,000 after buying an additional 37,980 shares during the last quarter.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.